HONG KONG, July 23, 2014 /PRNewswire-FirstCall/ -- China
Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"),
China's leading provider of cord
blood collection, laboratory testing, hematopoietic stem cell
processing, and stem cell storage services, and Cordlife Group
Limited ("Cordlife"), a multi-product healthcare company
catering to the mother and child segment, today announced that the
two companies have joined forces in assisting patients across the
PRC, Singapore, Hong Kong, Indonesia, India, the
Philippines and Malaysia to
identify suitable cord blood matching units for stem cell
therapy.
Under the Memorandum of Understanding signed between the two
companies, Cordlife, on behalf of its patients who are in need of
cord blood stem cell therapy, can facilitate the process by
providing relevant information to CCBC, who will then perform
searches for possible matching units among its donated cord blood
samples in the PRC. For patients who reside in the PRC, CCBC may
seek Cordlife's assistance or contacts to source possible cord
blood unit matches in the relevant public cord blood registries in
the regions where Cordlife operates, which include Hong Kong, Singapore, India, Indonesia, the
Philippines, and Malaysia.
Mr. KAM Yuen, Chairman of China Cord Blood Corporation
commented, "Both CCBC and Cordlife share a common vision which is
to enhance people's lives through the widening of umbilical cord
blood stem cells application services. Our proposed collaboration
will assist families in the PRC and other parts of Asia who face difficulties obtaining a
matching cord blood unit to widen their search, resulting in the
increased likelihood of receiving treatment."
Mr. Jeremy YEE, Executive Director and Chief Executive Officer
of Cordlife said, "We are glad to collaborate with CCBC in a joint
effort to make cord blood stem cell therapy more widely available
to our patients, particularly those who have difficulty finding a
matching cord blood unit. Our two companies share a common goal of
providing the best services, saving lives and improving quality of
life for people in the Asia
region."
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest umbilical
cord blood banking operator in China in terms of geographical coverage and
the only cord blood banking operator with multiple licenses.
Under current PRC government regulations, only one licensed
cord blood banking operator is permitted to operate in each
licensed region and only seven licenses have been authorized as of
today. China Cord Blood Corporation provides cord blood
collection, laboratory testing, hematopoietic stem cell processing,
and stem cell storage services. For more information, please
visit our website at http://www.chinacordbloodcorp.com.
About Cordlife Group Limited (Bloomberg stock code: CLGL
SP)
Incorporated in May 2001, Cordlife
Group Limited ("Cordlife") is a multi-product healthcare company
catering to the mother and child segment and a leading cord blood
and umbilical cord lining banking services provider. Today,
Cordlife operates the largest[1] private cord blood
banks in Singapore, the Philippines and Indonesia; and is amongst the top three market
leaders in Hong Kong and
India. Cordlife also holds 10% and
31.81% stakes in China Cord Blood
Corporation and StemLife Berhad respectively, both of which are
their countries' largest cord blood bank operators. For more
information, please visit www.cordlife.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events, performance and
results of operations, and underlying assumptions and other
statements that are other than statements of historical facts.
These statements are subject to uncertainties and risks including,
but not limited to, product and service demand and acceptance,
changes in technology, economic conditions, the impact of
competition and pricing, government regulation, and other risks
contained in statements filed from time to time with the U.S.
Securities and Exchange Commission. All such forward-looking
statements, whether written or oral, and whether made by or on
behalf of the Company, are expressly qualified by the cautionary
statements and any other cautionary statements which may accompany
the forward-looking statements. In addition, the Company disclaims
any obligation to update any forward-looking statements to reflect
events or circumstances after the date hereof.
For more information, please contact:
China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com
ICR, Inc.
Mr. Bill Zima
Tel: (+86) 10-6583-7511 (China) or
(+1) 646-405-5185 (U.S.)
Email: william.zima@icrinc.com
[1]
|
Source : Deloitte
& Touche Financial Advisory Services Limited report, 10 April
2013
|
SOURCE China Cord Blood Corporation